

7/15/02

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.			
Typed or Printed Name		Donna Macedo	
Signature	<i>D. Macedo</i>	Date	3/12/02

PRELIMINARY AMENDMENT		RECEIVED	
Address to: Commissioner for Patents Washington, D.C. 20231	Attorney Docket Confirmation No.	CLON037CON	APR 03 2002
	First Named Inventor	Perry	
	Application Number	09/839,696	TECH CENTER 1600/2900
	Filing Date	April 19, 2001	
	Group Art Unit	1653	
	Examiner Name	Unassigned	
	Title	Novel Method for Purification of Recombinant Proteins	

Sir:

Prior to examination of the application on the merits, please enter the following amendments:

### AMENDMENTS

#### In the claims:

Please add the following new claims:

--24. (New) An immobilized metal ion affinity chromatography complex comprising:

- (a) an aspartate metal chelating ligand; and
- (b) a transition metal ion complexed to said aspartate metal chelating ligand.

25. (New) The immobilized metal ion affinity chromatography complex according to Claim 24, wherein said aspartate ligand is a tetradentate ligand.

23/2004 TJOHNS04 00000004 500815 09839696

FC:120126. (New) The immobilized metal ion affinity chromatography complex according to Claim 24, wherein said transition metal is complexed to said ligand in octahedral geometry.

27. (New) The immobilized metal ion affinity chromatography complex according to Claim 24, wherein said transition metal ion is selected from the group consisting of  $\text{Fe}^{2+}$ ,  $\text{Co}^{2+}$ ,  $\text{Ni}^{2+}$ ,  $\text{Cu}^{2+}$  and  $\text{Zn}^{2+}$ .

04/01/2002 NBERHE 00000040 500815 09839696

01 FC:103 162.00 CH

36. (New) The method according to Claim 31, wherein said complex offers two available valencies.
- B1 37. (New) The immobilized metal ion affinity chromatography complex according to Claim 36, wherein said two available valencies form strong, reversible complexes with adjacent histidine residues on the surface of said protein. --
- 


**REMARKS UNDER 37 CFR § 1.111**

Newly presented Claims 24-37 find support throughout the specification and originally pending claims. As such, there entry and examination by the Examiner is respectfully requested.

The Commissioner is hereby authorized to charge any underpayment of fees associated with this communication, including any necessary fees for extensions of time, or credit any overpayment to Deposit Account No. 50-0815, order number CLON37DIV.

Respectfully submitted,  
BOZICEVIC, FIELD & FRANCIS LLP

Date: 3.12.02

By:   
Bret E. Field  
Registration No. 37,620

BOZICEVIC, FIELD & FRANCIS LLP  
200 Middlefield Road, Suite 200  
Menlo Park, CA 94025  
Telephone: (650) 327-3400  
Facsimile: (650) 327-3231